Enpowering Progression Risk of Cerebral Amyloid Angiopathy

Cerebral amyloid angiopathy (CAA) is a microangiopathy characterized by the progressive deposition of β-amyloid in cerebral vessel walls, contributing to intracerebral hemorrhages, cognitive decline, and other clinical manifestations. Despite recent advances in diagnosis and understanding, many pathogenic, prognostic, and therapeutic aspects remain unclear. Study Objective: PRIORITY is a prospective observational study aimed at identifying clinical, neuroradiological, and biochemical biomarkers that could improve early diagnosis, risk stratification, and the identification of personalized therapeutic targets for CAA.

NCT Number	NCT06960538
Lead Sponsor	Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
Conditions	Cerebral Amyloid Angiopathy, CAA - Cerebral Amyloid Angiopathy
Enrollment	200 participants
Start Date	2021-11-01
Primary Completion	2025-09-30 (estimated)
Study Completion	2025-09-30 (estimated)
Updated on ClinicalTrials.gov	2026-03-27